AQST Aquestive Therapeutics Inc.

6.29
+0.05  (+1%)
Previous Close 6.24
Open 6.21
Price To Book 15.72
Market Cap 157092794
Shares 24,975,007
Volume 82,826
Short Ratio
Av. Daily Volume 105,153

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date November 30, 2019.
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
NDA filing due early 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
CRL issued January 30, 2019 through partner Sunovion (private company).
APL-130277
Parkinson’s Disease with motor fluctuations

Latest News

  1. Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019
  2. Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
  3. Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
  4. Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
  5. Aquestive Therapeutics: 4Q Earnings Snapshot
  6. Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  7. Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
  8. Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019
  9. Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
  10. Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation
  11. Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
  12. Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen
  13. Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer
  14. Aquestive Therapeutics, Inc.’s (NASDAQ:AQST) Shift From Loss To Profit
  15. Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters
  16. Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018
  17. Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  18. Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
  19. Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability
  20. Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings